Literature DB >> 17065402

Hypertensive effect of calcilytic NPS 2143 administration in rats.

Apolonia Rybczynska1, Artur Lehmann, Anna Jurska-Jasko, Konrad Boblewski, Czeslawa Orlewska, Henryk Foks, Krystyna Drewnowska.   

Abstract

Secretion of parathormone (PTH), the main parathyroid hormone, which is under the control of the calcium sensing receptor, might be inhibited by calcimimetics and stimulated by calcilytics. Parathyroid glands also secrete parathyroid hypertensive factor. Recently, it was shown that calcimimetic NPS R-568 induced decreased blood pressure in spontaneously hypertensive rats (SHR) in the presence of parathyroid glands. Therefore, the aim of this study was to determine whether administration of the calcilytic NPS 2143 provoked an increase of mean arterial blood pressure (MAP) in normotensive rats. We used male Wistar rats anaesthetized with thiopental. Clearance experiments were performed and the effect of bolus, 1 mg/kg body weight i.v. of NPS 2143 on MAP in the presence and absence of thyroparathyroidectomy (TPTX) was monitored continuously. Calcilytic properties of NPS 2143 were confirmed directly by a significant (P < 0.05) increase of plasma PTH concentration, and indirectly by a rise of plasma Ca(2+) concentration and urinary fractional phosphate excretion (FE Pi). NPS 2143 administration markedly (P < 0.05) increased MAP, calculated as the difference ( Delta ) in MAP between sequential measurements and the time of bolus injection of calcilytic. The observed increase of blood pressure in the NPS 2143 group was also significant (P < 0.05) compared with the control group. Performance of TPTX prevented the hypertensive effect of NPS 2143. We conclude that NPS 2143 is responsible for increased blood pressure in rats in the presence of parathyroid glands.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17065402     DOI: 10.1677/joe.1.06924

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  8 in total

1.  Activation of the calcium-sensing receptor before renal ischemia/reperfusion exacerbates kidney injury.

Authors:  Laurent Weekers; Pascal de Tullio; Christophe Bovy; Laurence Poma; Raphaël Marée; Catherine Bonvoisin; Jean-Olivier Defraigne; Jean-Marie Krzesinski; François Jouret
Journal:  Am J Transl Res       Date:  2015-01-19       Impact factor: 4.060

Review 2.  New functional aspects of the extracellular calcium-sensing receptor.

Authors:  Hakan R Toka
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-07       Impact factor: 2.894

Review 3.  The calcium-sensing receptor and calcimimetics in blood pressure modulation.

Authors:  Sanela Smajilovic; Shozo Yano; Reza Jabbari; Jacob Tfelt-Hansen
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

4.  Involvement of the calcium-sensing receptor in human taste perception.

Authors:  Takeaki Ohsu; Yusuke Amino; Hiroaki Nagasaki; Tomohiko Yamanaka; Sen Takeshita; Toshihiro Hatanaka; Yutaka Maruyama; Naohiro Miyamura; Yuzuru Eto
Journal:  J Biol Chem       Date:  2009-11-05       Impact factor: 5.157

5.  Kokumi substances, enhancers of basic tastes, induce responses in calcium-sensing receptor expressing taste cells.

Authors:  Yutaka Maruyama; Reiko Yasuda; Motonaka Kuroda; Yuzuru Eto
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

6.  Reduced Expression of the Extracellular Calcium-Sensing Receptor (CaSR) Is Associated with Activation of the Renin-Angiotensin System (RAS) to Promote Vascular Remodeling in the Pathogenesis of Essential Hypertension.

Authors:  Yuan-Yuan Qu; Jing Hui; La-Mei Wang; Na Tang; Hua Zhong; Yong-Min Liu; Zhen Li; Qian Feng; Fang He
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

7.  The calcilytics Calhex-231 and NPS 2143 and the calcimimetic Calindol reduce vascular reactivity via inhibition of voltage-gated Ca2+ channels.

Authors:  Harry Z E Greenberg; Kazi S Jahan; Jian Shi; W-S Vanessa Ho; Anthony P Albert
Journal:  Eur J Pharmacol       Date:  2016-10-08       Impact factor: 4.432

8.  Calcimimetic R568 reduced the blood pressure and improved aortic remodeling in spontaneously hypertensive rats by inhibiting local renin-angiotensin system activity.

Authors:  Ruixia Sun; Wenwen Zhang; Hua Zhong; Lamei Wang; Na Tang; Yongmin Liu; Yongli Zhao; Tian Zhang; Fang He
Journal:  Exp Ther Med       Date:  2018-09-13       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.